Investee Company Update

RNS Number : 3783I

FastForward Innovations Limited

19 June 2017

 

19 June 2017

FastForward Innovations Limited

("FastForward"")

Intensity Therapeutics Issued New Patents

 for Technology Platform

·      US Patent 9,636,406 broadens existing claims for the Intensity's proprietary technology

·      Australia intends to grant Intensity patent 2013318338

Intensity Therapeutics, Inc., ("Intensity" or "the Company") in which FastForward has a holding of 2.118%, is a privately held biotechnology company developing proprietary cancer immunotherapy products, and has announced that the United States Patent and Trademark Office (PTO) has issued the Company patent 9,636,406. In addition, Intensity noted that the Australian PTO intends to grant Intensity patent 2013318338.

The Intensity announcement reads as follows:

"Intensity's DfuseRx^SM platform has identified our lead drug, INT230-6. This novel product, now in clinical trials, has shown great promise in regressing tumors and extending life in animal models of metastatic cancer," said Intensity's President and CEO, Lewis H. Bender. "The newly issued U.S. patent and soon-to-be issued Australian patent allow us to protect our unique technology. The Company now has multiple issued patents and several patent applications in the U.S. and countries around the world. U.S. patent 9,636,406 and near-term issuance of Australian patent 2013318338 increases the likelihood that our products can be secured in important markets."

About INT230-6 

INT230-6 is a novel, anti-cancer drug for direct intratumoral injection. The product contains potent anti-cancer agents that disperse throughout tumors and diffuse into cancer cells. INT230-6 was identified from Intensity's DfuseRx^SM platform. In preclinical studies INT230-6 eradicated tumors by a combination of direct tumor kill coupled with recruitment of dendritic cells to the tumor micro-environment that stimulated anti-cancer T-cell activation. INT230-6 provides complete responder animals with long-term, durable protection from multiple re-inoculations of the initial cancer and resistance to other cancers. INT230-6 is being evaluated in clinical study, IT-01. Further information on the human trial can be found at www.clinicaltrials.gov (NCT#03058289).

About Intensity Therapeutics, Inc. 

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company whose mission is to greatly extend the lives of patients with cancer. Intensity Therapeutics is pioneering a new immune-based approach to treat cancer. The Company uses its DfuseRx^SM platform technology to create new drug formulations that disperse throughout a tumor and diffuse into cancer cells. Drug products created using the technology are capable of attenuating (killing) a tumor in a manner that allows for the adaptive immune system to recognize the cancer and attack distal tumors and micrometastases. Further information can be found at www.intensitytherapeutics.com.

For further information please visit www.fstfwd.co or contact:

FastForward  Innovations Limited [e-mail]   Josh Epstein/ Ian Burns

Beaumont Cornish Limited (Nomad) Tel: [phone] James Biddle / Michael Cornish

Optiva Securities Limited (Broker) Tel: [phone] Ed McDermott

CAUTIONARY STATEMENT

The AIM Market of London Stock Exchange plc does not accept responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of FastForward Innovations Ltd. There can be no assurance that such statements will prove to be accurate, achievable or recognizable in the near term.

Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. FastForward Innovations assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

 

END

 

 

NRAOKADDPBKDBAD